Authors
Loading...
Analysis uncovers distinct inflammatory profiles in lower-risk MDS, suggesting varying responses to erythropoietin stimulating agents.
Pourcq et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: